Communiqués HLS Therapeutics Inc. Toronto S.E.

Actions

HLS

CA05328X1015

Temps Différé Toronto S.E. 17:18:25 05/10/2021			Varia. 5j.	Varia. 1 janv.
18,15 ^CAD	-0,06 %		-1,25 %	+0,89 %

Communiqués

10/08/20	HLS Therapeutics : to Present at the Canaccord Genuity 40th Annual Growth Conference	AQ
07/08/20	HLS Therapeutics : to Present at the Canaccord Genuity 40th Annual Growth Conference	AQ
06/08/20	HLS Therapeutics : Announces Q2 2020 Financial Results	AQ
30/07/20	HLS Therapeutics : to Host Q2 2020 Financial Results Conference Call	AQ
21/07/20	HLS Therapeutics : IIROC Trade Resumption - HLS	AQ
21/07/20	HLS Therapeutics : welcomes both CADTH's recommendation to reimburse Vascepa for patients with established cardiovascular disease	AQ
20/07/20	HLS Therapeutics : welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price	AQ
20/07/20	HLS Therapeutics : IIROC Trading Halt - HLS	AQ
22/06/20	HLS Therapeutics : Reports Annual Meeting Results	AQ
19/06/20	HLS Therapeutics : Reports Annual Meeting Results	AQ
17/06/20	HLS Therapeutics : to Present at the Raymond James Human Health Innovation Conference	AQ
10/06/20	HLS Therapeutics : Confirms Annual Shareholders' Meeting	AQ
02/06/20	HLS Therapeutics : to Become Distributor of the Saladax MyCare Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents	AQ
01/06/20	HLS Therapeutics : to Present at the Jefferies Virtual Healthcare Conference	AQ
01/06/20	HLS Therapeutics : to Become Distributor of the Saladax MyCare™ Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents	AQ
22/05/20	HLS Therapeutics : Supports Trial to Investigate the Effects of Vascepa against COVID-19	AQ
21/05/20	HLS Therapeutics : Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19	AQ
07/05/20	HLS Therapeutics : Announces Q1 2020 Financial Results	AQ
30/04/20	HLS Therapeutics : to Host Q1 2020 Financial Results Conference Call	AQ
31/03/20	HLS Therapeutics : Comments on U.S. District Court Decision on Amarin Patents	AQ
19/03/20	HLS Therapeutics : Announces Fourth Quarter and Fiscal 2019 Financial Results	AQ
27/02/20	HLS Therapeutics : to Host Q4 and Fiscal 2019 Financial Results Conference Call	AQ
29/01/20	HLS Therapeutics : Provides Investor Update on the Canadian Launch of Vascepa	AQ
28/01/20	HLS Therapeutics : Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)	AQ
24/01/20	HLS Therapeutics : Files New Drug Submission for PERSERIS in Canada	AQ